G1 Therapeutics' GAAP loss for 2022 was $147.56 million, down 0.5% from $148.35 million in the previous year. Revenue increased 63% to $51.301 million from $31.476 million a year earlier.
G1 Therapeutics' GAAP loss for 2022 was $147.56 million, down 0.5% from $148.35 million in the previous year. Revenue increased 63% to $51.301 million from $31.476 million a year earlier. 
investor.g1therapeutics.com
English (US) 